142 related articles for article (PubMed ID: 19836653)
41. Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Huang J; Wang T; Huang Y
Med Oncol; 2013 Mar; 30(1):436. PubMed ID: 23283650
[No Abstract] [Full Text] [Related]
42. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
43. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Berchem G; Dewilde S; Mahassen P
Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172
[TBL] [Abstract][Full Text] [Related]
44. Sunitinib and hypothyroidism.
Wolter P; Dumez H; Schöffski P
N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
[No Abstract] [Full Text] [Related]
45. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Rini BI; Choueiri TK; Elson P; Khasawneh MK; Cotta C; Unnithan J; Wood L; Mekhail T; Garcia J; Dreicer R; Bukowski RM
Cancer; 2008 Sep; 113(6):1309-14. PubMed ID: 18618496
[TBL] [Abstract][Full Text] [Related]
46. New therapeutic options for renal cell carcinoma.
Stadler W
Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
[No Abstract] [Full Text] [Related]
47. Fatigue with sunitinib-induced hypothyroidism.
Senior K
Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
[No Abstract] [Full Text] [Related]
48. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
Edeline J; Laguerre B; Rolland Y; Patard JJ
Ann Oncol; 2010 Jan; 21(1):186-7. PubMed ID: 19875754
[No Abstract] [Full Text] [Related]
49. Sunitinib-induced thrombotic microangiopathy.
Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K
J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203
[TBL] [Abstract][Full Text] [Related]
50. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.
Gomez-Abuin G; Karam AA; Mezzadri NA; Bas CA
Clin Genitourin Cancer; 2009 Jan; 7(1):62-3. PubMed ID: 19213671
[TBL] [Abstract][Full Text] [Related]
51. Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.
Lamarca A; Feliu J; Barriuso J
Br J Cancer; 2012 Mar; 106(6):1246. PubMed ID: 22294185
[No Abstract] [Full Text] [Related]
52. Sunitinib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
[TBL] [Abstract][Full Text] [Related]
53. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Grossmann M; Premaratne E; Desai J; Davis ID
Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
[TBL] [Abstract][Full Text] [Related]
54. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T; Wong R; Davis ID
Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
[No Abstract] [Full Text] [Related]
55. Sunitinib induces hypothyroidism with a markedly reduced vascularity.
Makita N; Miyakawa M; Fujita T; Iiri T
Thyroid; 2010 Mar; 20(3):323-6. PubMed ID: 20187785
[TBL] [Abstract][Full Text] [Related]
56. Lower limbs erosions induced by sunitinib.
Kluger N; Chapelle A; Jacot W; Guillot B
Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
[No Abstract] [Full Text] [Related]
57. Lung Aspergillosis in renal cell carcinoma patient treated with sunitinib.
Visvardis EE; Gao F; Paes MN; Duprez O; Waxman J
QJM; 2012 Jul; 105(7):689-92. PubMed ID: 21693543
[No Abstract] [Full Text] [Related]
58. The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.
Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb S; Shamash J; Stockdale A; Lim L; Nathan P; Chowdury S
Eur J Cancer; 2013 Mar; 49(4):986-7. PubMed ID: 23138000
[No Abstract] [Full Text] [Related]
59. Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.
Lim TJ; Lee JH; Chang SG; Lee CH; Min GE; Yoo KH; Jeon SH
Urol Int; 2010; 85(4):475-8. PubMed ID: 20975258
[TBL] [Abstract][Full Text] [Related]
60. PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinoma.
Sun M; Larcher A; Schiffmann J; Karakiewicz PI
J Clin Oncol; 2014 Nov; 32(33):3783. PubMed ID: 25267763
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
